Searched for
RAMESH SWAMINATHAN
Thiruparankundram hill lamp row: SC dismisses plea for action against officialsThe Supreme Court has upheld a Madras High Court decision. The High Court had dismissed a plea seeking action against officials. These offi...- PM Modi maintaining 'studious silence' on key issues affecting people of UP: Congress' Jairam RameshCongress has accused Prime Minister Narendra Modi of maintaining a "studious silence" on key issues affecting the people of Uttar Pradesh, ...
- Centre gave Bharat Ratna to Chaudhary Charan Singh, but doing 'injustice' to farmers: Jairam RameshAddressing a press conference in Chhattsigarh's Surguja district headquarters Ambikapur during the Congress' ongoing 'Bharat Jodo Nyay Yatr...
- Narasimha Rao, Charan Singh, Swaminathan will always be 'Bharat ke Ratna': CongressThe Congress on Friday said former prime ministers P V Narasimha Rao and Charan Singh and Green Revolution pioneer M S Swaminathan were, ar...
- What triggered Lupin’s growth spurt & can it be sustained?"From Q2 onwards, we expected to get back to double digit growth and are very happy that it is happening in Q1 itself. The growth year on y...
- An old hand’s back, but can Lupin and he make it count?Now that Swaminathan is back, Lupin’s shareholders may expect improvement in the company’s performance.
- Lupin CFO quits, to pursue opportunities outside pharmaSwaminathan as the CFO of Lupin, was part of some of company's biggest mergers and acquisition in US and Japan
- Lupin still on track to meet $800-million FY19 sales target: Ramesh SwaminathanThings not as bad as they were in the past and should be looking better, says Lupin CFO.
- For every rupee depreciation, we expect to add Rs 40 cr to bottom line: Ramesh Swaminathan, Lupin“Between 25% and 30% of our total exposures are hedged.”
- For Lupin, uncertainties of FY18 would continue in FY19: Ramesh Swaminathan“Biosimilars, complex generics and speciality would be key elements of Lupin strategy going forward”
- Only 'immaterial dent' due to FDA action: LupinThe Mumbai-based company received two warning letters last week from the US Food and Drug Administration for its manufacturing units in Goa...
- Growth will come on the back Gavis consolidation: Ramesh Swaminathan, CFO, Lupin"This year Gavis will actually add tremendously to the growth. We also have other molecules to launch after Glumetza and Fortament gets pha...
- Next 2-3 years to be good for the company: Ramesh Swaminathan, LupinIn an interaction with ET Now, Ramesh Swaminathan, CFO, Lupin, talks about company's prospectus and expansion plans.
- Looking at low cost R&D manufacturing in India: Ramesh Swaminathan, Lupin'If you look at the Indian pharmaceutical industry today, our paradigm today is low-cost manufacturing in India, low-cost R&D and we have b...
- Budget 2015 fell short of any kind of road map for the pharma sector: Ramesh Swaminathan of LupinOverall, the budget fell short of any kind of road map for the pharma sector in the form of reforms that would incentivize R&D or manufactu...
- Lupin rallies over 1% on acquisition plans, USFDA HIV drug approvalLupin Ltd rallied as much as 1.5 per cent in trade on Monday on reports that that the drug major is eyeing acquisitions in various global m...
- Continuously evaluating opportunities for tie-ups with large MNCs: Ramesh Swaminathan, Lupin'We do keep talking to various big pharma companies for various kinds of alliance. So potentially I cannot speak about any deal until it ac...
- Have about 200 drug filings in US, 100 have got approvals: Ramesh Swaminathan, Lupin'We do expect nicotinic acid and Aspen to be launched by the end of this quarter,' says Ramesh Swaminathan.
- Ministry considering bio-shields against tsunamiThe idea of promoting mangroves and other biological shields to provide a 'speed breaker' was suggested by agricultural scientist and RS MP...
- Lupin appoints Swaminathan as PresidentPharma company Lupin Limited appoints Ramesh Swaminathan as its President for finance and planning.
Load More
